Pharma Partner Identification Guide

5-Step Partner Identification Framework

Most BD teams approach partner identification backwards — they start with a list of large pharma companies and work down by size. This leads to wasted meetings with companies that have no strategic urgency to do a deal. The data-driven approach starts with urgency signals and works outward to identify the 8-15 companies most likely to pay the highest price on the shortest timeline.

Step 1: Map Your Asset's Competitive Position

Before identifying partners, define exactly what you are selling. Map your asset against every competitor in development — same target, same indication, same patient population. Understand whether you are first-in-class (premium pricing, larger buyer pool) or best-in-class (differentiation narrative required). This mapping determines which buyers have the most urgent need for your asset versus alternatives.

Step 2: Identify Pipeline Gaps

Pipeline gaps are the strongest predictor of deal-making intent. A company with no Phase 2+ assets in a TA where it has significant revenue exposure (due to patent cliffs) is a high-urgency buyer. Screen 850+ companies for gaps in your specific therapeutic area and indication. The most valuable gaps are those created by recent clinical failures, discontinuations, or upcoming LOE (loss of exclusivity) events.

Step 3: Score Intent Signals

Pipeline gaps tell you who needs an asset. Intent signals tell you who is ready to act. The Pharma Intent Score synthesizes 8 factors into a single predictive metric, backtested against 378 completed transactions with demonstrated accuracy.

Step 4: Assess Strategic and Financial Fit

Not every company with a pipeline gap and high intent is the right partner. Strategic fit encompasses commercial infrastructure in your regions, regulatory expertise in your indication, and cultural alignment on development approach. Financial fit means the company can afford your deal — a mid-cap pharma with $2B in cash may offer a better partnership than a mega-cap that is digesting a recent $20B acquisition.

Step 5: Prioritize and Sequence

Rank your target partners into three tiers: Tier 1 (3-5 companies with highest intent scores and strategic fit — approach first), Tier 2 (5-7 companies with strong fit but moderate urgency — approach in parallel as a competitive dynamic), and Tier 3 (3-5 backup options). Approaching Tier 1 and Tier 2 simultaneously creates the competitive tension that drives upfront premiums of 20-40%.

What Data Matters in Partner Selection

Four categories of data separate informed partner selection from guesswork. Each category contributes a distinct signal that, combined, predicts deal likelihood and expected economics.

Patent cliffs. The single strongest predictor of deal urgency. When a company faces LOE on a $5B+ product in 2-3 years with no internal replacement, it will pay premium prices for late-stage assets in the same therapeutic area. Our database tracks patent cliff timing for all 850+ profiled companies.

Pipeline gaps. Beyond patent cliffs, analyze where each company's pipeline is thin relative to its strategic priorities. A company with 15 oncology assets but zero immunology assets that has publicly committed to building an immunology franchise is a high-intent buyer for immunology assets.

Deal velocity. Companies that have closed 5+ deals in the past 24 months have active BD teams, established deal processes, and board-level comfort with deal-making. Companies with zero deals in 24 months may have internal barriers (reorganization, financial constraints, risk aversion) that extend timelines regardless of asset fit.

Competitive pressure. When a peer company acquires a major asset in your therapeutic area, every other company in that space re-evaluates its pipeline. The “fear of missing out” effect is measurable: in our data, deal velocity in a TA increases 30-50% in the 6 months following a mega-deal in that space.

How Intent Scoring Predicts Deal Likelihood

The Pharma Intent Score is not theoretical — it is backtested against 378 completed transactions with measurable predictive accuracy. Companies scoring above 80 (top quintile) closed deals at 2.3x the rate of companies scoring 40-60, and paid 15-20% higher upfronts when they did close.

Partnering Conference Preparation Timeline

Whether you are preparing for JPM, BIO International, or ASCO, the partner identification timeline should begin 4-6 months before the event. Companies that start at the conference are 40% slower to close deals because they are competing for attention with every other company in attendance.

Frequently Asked Questions

How do I identify the best pharma partner for my asset?

Start with pipeline gap analysis — identify companies with urgent needs in your therapeutic area due to patent cliffs, clinical failures, or competitive pressure. Score them on intent signals (deal velocity, financial capacity, public statements) using the Partner Matching engine. The best partner is the company with the highest urgency and best strategic fit, not the largest company.

What is a Pharma Intent Score?

An 8-factor predictive model that forecasts which companies are most likely to do a deal in a specific therapeutic area. Factors include pipeline gaps, patent cliff timing, deal velocity, competitive pressure, and financial capacity. Backtested against 378 deals. Companies scoring above 80 close 2.3x faster and pay 15-20% higher upfronts.

How many companies should I approach?

Target 8-15 companies for initial conversations, with the goal of advancing 3-5 to term sheet stage. Fewer than 3 serious bidders weakens your negotiating position. More than 15 creates management overhead without proportional benefit. Quality of targeting matters more than quantity.

When should I start partner identification before a conference?

Four to six months before JPM, BIO, or ASCO. Use months 1-2 for identification and scoring, months 3-4 for outreach and CDAs, months 5-6 for pre-meeting data packages. Companies that start 6 months early close 40% faster than those who begin at the conference.

What data signals predict pharma deal-making intent?

Eight key signals: patent cliff proximity (strongest), recent pipeline failures, high deal velocity, competitor acquisitions in your space, public strategic commitments, leadership changes, financial capacity, and geographic fit. The Pharma Intent Score combines all eight into a single predictive metric. See our asset valuation guide for how partner selection affects deal value.